Yusuke Suzuki

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4348338/publications.pdf

Version: 2024-02-01

122 papers	3,957 citations	147801 31 h-index	144013 57 g-index
124 all docs	124 docs citations	124 times ranked	3050 citing authors

#	Article	IF	Citations
1	Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan. Clinical and Experimental Nephrology, 2022, 26, 316-322.	1.6	18
2	IgA Nephropathy with Gross Hematuria Following COVID-19 mRNA Vaccination. Internal Medicine, 2022, 61, 1033-1037.	0.7	16
3	Negative-pressure wound therapy is effective for peritoneal dialysis catheter exit-site management in the early postoperative period. Scientific Reports, 2022, 12, 70.	3.3	2
4	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. Kidney International Reports, 2022, 7, 993-1003.	0.8	18
5	Association of cardiac autonomic neuropathy assessed by heart rate response during exercise with intradialytic hypotension and mortality in hemodialysis patients. Kidney International, 2022, 101, 1054-1062.	5.2	2
6	Progranulin and Its Receptor Predict Kidney Function Decline in Patients With Type 2 Diabetes. Frontiers in Endocrinology, 2022, 13, 849457.	3.5	5
7	Coronary Artery Bypass Grafting in Patients with Chronic Kidney Disease: Chronic Kidney Disease Has an Independent Adverse Effect on the Long-Term Outcome of Coronary Artery Bypass Grafting. BioMed Research International, 2022, 2022, 1-14.	1.9	1
8	Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy. Kidney International, 2022, 102, 160-172.	5.2	25
9	FC051: Atacicept Reduces Serum ANTI-GD-IGA1 Levels in IgAN Patients. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	1
10	Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy. Journal of Clinical Medicine, 2022, 11, 3173.	2.4	6
11	Predictors of early remission of proteinuria in adult patients with minimal change disease: a retrospective cohort study. Scientific Reports, 2022, 12, .	3.3	3
12	Fractional excretion of tumor necrosis factor receptorÂ1 and 2 in patients with typeÂ2 diabetes and normal renal function. Journal of Diabetes Investigation, 2021, 12, 382-389.	2.4	9
13	Renal pathological analysis using galactose-deficient IgA1-specific monoclonal antibody is a strong tool for differentiation of primary IgA nephropathy from secondary IgA nephropathy. CEN Case Reports, 2021, 10, 17-22.	0.9	11
14	Continuous extracorporeal treatments in a dialysis patient with COVID-19. CEN Case Reports, 2021, 10, 172-177.	0.9	7
15	Impact of the number of steroid pulses in tonsillectomy combined with steroid pulse therapy: a nationwide retrospective study in Japan. Clinical and Experimental Nephrology, 2021, 25, 19-27.	1.6	4
16	LCC18 , a benzamideâ€linked small molecule, ameliorates IgA nephropathy in mice. Journal of Pathology, 2021, 253, 427-441.	4.5	5
17	Ischemic Stroke Induces Rapid Renal Oxidative Stress and Lipometabolic Change. Juntendo Medical Journal, 2021, 67, 39-45.	0.1	0
18	A case of hereditary angioedema due to C1-inhibitor deficiency with recurrent abdominal pain diagnosed 40 years after the occurrence of the initial symptom. Clinical Journal of Gastroenterology, 2021, 14, 1175-1179.	0.8	2

#	Article	IF	Citations
19	Galactose-deficient IgA1 and nephritis-associated plasmin receptors as markers for IgA-dominant infection-related glomerulonephritis. Medicine (United States), 2021, 100, e24460.	1.0	6
20	The Phenotypic Difference of IgA Nephropathy and its Race/Gender-dependent Molecular Mechanisms. Kidney360, 2021, 2, 1339-1348.	2.1	15
21	Utility of remission criteria for the renal prognosis of IgA nephropathy. Clinical and Experimental Nephrology, 2021, 25, 988-995.	1.6	3
22	Association between social frailty as well as early physical dysfunction and exercise intolerance among older patients receiving hemodialysis. Geriatrics and Gerontology International, 2021, 21, 664-669.	1.5	8
23	Association Between Kidney Function Decline and Baseline TNFR Levels or Change Ratio in TNFR by Febuxostat Chiefly in Non-diabetic CKD Patients With Asymptomatic Hyperuricemia. Frontiers in Medicine, 2021, 8, 634932.	2.6	5
24	Are there animal models of IgA nephropathy?. Seminars in Immunopathology, 2021, 43, 639-648.	6.1	10
25	COVID-19-induced acute renal tubular injury associated with elevation of serum inflammatory cytokine. Clinical and Experimental Nephrology, 2021, 25, 1240-1246.	1.6	16
26	Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy. Kidney International, 2021, 100, 364-376.	5.2	25
27	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, 753-779.	5.2	325
28	Differential organ-specific inflammatory response to progranulin in high-fat diet-fed mice. Scientific Reports, 2021, 11, 1194.	3.3	7
29	Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2021, 32, 436-447.	6.1	34
30	Effect of blood volume change related to intensity of intradialytic aerobic exercise on hemodialysis adequacy: a pilot study. International Urology and Nephrology, 2021, , 1.	1.4	1
31	TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6â€“mediated pathways in IgA nephropathy. Kidney International, 2020, 97, 340-349.	5.2	78
32	Efficacy of endoscopic sinus surgery for eosinophilic chronic rhinosinusitis with asthma. Allergology International, 2020, 69, 144-145.	3.3	6
33	Thrombotic microangiopathy in dasatinib-treated patients with chronic myeloid leukemia. Journal of Onco-Nephrology, 2020, 4, 41-45.	0.6	1
34	P0350THE DURATION OF PROTEINURIA REMISSION AND CLINICAL OUTCOMES IN IGA NEPHROPATHY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
35	P0505COST ANALYSIS OF SCREENING FOR IGA NEPHROPATHY USING NOVEL BIOMARKERS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
36	Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases. BMC Nephrology, 2020, 21, 402.	1.8	11

#	Article	IF	Citations
37	Rapid progression to end-stage renal disease in a child with IgA-dominant infection-related glomerulonephritis associated with parvovirus B19. CEN Case Reports, 2020, 9, 423-430.	0.9	5
38	Emergent initiation of dialysis is related to an increase in both mortality and medical costs. Scientific Reports, 2020, 10, 19638.	3.3	10
39	IgA Nephropathy Benefits from Compound K Treatment by Inhibiting NF-Î²B/NLRP3 Inflammasome and Enhancing Autophagy and SIRT1. Journal of Immunology, 2020, 205, 202-212.	0.8	22
40	Circulating Tumor Necrosis Factor Receptors: A Potential Biomarker for the Progression of Diabetic Kidney Disease. International Journal of Molecular Sciences, 2020, 21, 1957.	4.1	34
41	Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS). Clinical and Experimental Nephrology, 2020, 24, 526-540.	1.6	33
42	Crucial Role of AIM/CD5L in the Development of Glomerular Inflammation in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2020, 31, 2013-2024.	6.1	29
43	Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS). Clinical and Experimental Nephrology, 2020, 24, 893-909.	1.6	6
44	Lipopolysaccharide-Deficient Acinetobacter baumannii Due to Colistin Resistance Is Killed by Neutrophil-Produced Lysozyme. Frontiers in Microbiology, 2020, 11, 573.	3.5	26
45	Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool. Kidney International, 2020, 98, 1009-1019.	5.2	35
46	17. Novel Therapeutic Approaches Based on Recent Advance in Elucidation of Pathogenesis of IgA Nephropathy. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 1976-1982.	0.0	0
47	Multi-point analysis of airborne Japanese cedar (Cryptomeria japonica D. Don) pollen by Pollen Robo and the relationship between pollen count and the severity of symptoms. Aerobiologia, 2019, 35, 635-646.	1.7	3
48	Galactose-deficient IgA1 in skin and serum from patients with skin-limited and systemic IgA vasculitis. Journal of the American Academy of Dermatology, 2019, 81, 1078-1085.	1.2	15
49	208.â€ƒGALACTOSE DEFICIENT IGA1 (GD-IGA1) IN SKIN AND SERUM FROM PATIENTS WITH SKIN-LIMITED AND SYSTEMIC IGA VASCULITIS. Rheumatology, 2019, 58, .	1.9	2
50	Association Between Tonsillectomy and Outcomes in Patients With Immunoglobulin A Nephropathy. JAMA Network Open, 2019, 2, e194772.	5.9	59
51	Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Internal Medicine, 2019, 179, 942.	5.1	266
52	A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. Kidney International, 2019, 96, 104-116.	5.2	41
53	Exercise-Induced Acute Kidney Injury in a Police Officer with Hereditary Renal Hypouricemia. Case Reports in Nephrology and Dialysis, 2019, 9, 92-101.	0.6	10
54	A grading system that predicts the risk of dialysis induction in IgA nephropathy patients based on the combination of the clinical and histological severity. Clinical and Experimental Nephrology, 2019, 23, 16-25.	1.6	18

#	Article	IF	Citations
55	Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study. Clinical and Experimental Nephrology, 2018, 22, 1266-1280.	1.6	21
56	IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney International, 2018, 93, 700-705.	5.2	151
57	Enrichment of airborne Japanese cedar (Cryptomeria japonica) pollen in mountain ranges when passing through a front accompanying temperate low pressure. Aerobiologia, 2018, 34, 105-110.	1.7	6
58	Chronic intermittent hypoxia-mediated renal sympathetic nerve activation in hypertension and cardiovascular disease. Scientific Reports, 2018, 8, 17926.	3.3	28
59	Galactose-Deficient IgA1-Specific Antibody Recognizes GalNAc-Modified Unique Epitope on Hinge Region of IgA1. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2018, 37, 252-256.	1.6	9
60	The Xanthine Oxidase Inhibitor Febuxostat Suppresses the Progression of IgA Nephropathy, Possibly via Its Anti-Inflammatory and Anti-Fibrotic Effects in the gddY Mouse Model. International Journal of Molecular Sciences, 2018, 19, 3967.	4.1	10
61	Association between circulating tumor necrosis factor-related biomarkers and estimated glomerular filtration rate in type 2 diabetes. Scientific Reports, 2018, 8, 15302.	3.3	30
62	Murine Models of Human IgA Nephropathy. Seminars in Nephrology, 2018, 38, 513-520.	1.6	23
63	Suffocation due to Acute Airway Edema in a Patient with Hereditary Angioedema Highlighted the Need for Urgent Improvements in Treatment Availability in Japan. Internal Medicine, 2018, 57, 3193-3197.	0.7	11
64	Clinical predictive biomarkers for normoalbuminuric diabetic kidney disease. Diabetes Research and Clinical Practice, 2018, 141, 62-68.	2.8	29
65	Expression of Cathepsin L and Its Intrinsic Inhibitors in Glomeruli of Rats With Puromycin Aminonucleoside Nephrosis. Journal of Histochemistry and Cytochemistry, 2018, 66, 863-877.	2.5	6
66	Establishment of a novel mouse xenograft model of human uterine leiomyoma. Scientific Reports, 2018, 8, 8872.	3.3	9
67	Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy. PLoS ONE, 2018, 13, e0190967.	2.5	56
68	High doses of antipsychotic polypharmacy are related to an increase in serum levels of pentosidine in patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 76, 42-48.	4.8	8
69	Evaluation of Longâ€Term Combination Therapy With Peritoneal Dialysis and Hemodialysis. Therapeutic Apheresis and Dialysis, 2017, 21, 180-184.	0.9	19
70	Circulating TNF Receptors 1 and 2 Predict Mortality in Patients with End-stage Renal Disease Undergoing Dialysis. Scientific Reports, 2017, 7, 43520.	3.3	49
71	High serum soluble tumor necrosis factor receptor 1 predicts poor treatment response in acute-stage schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 76, 145-154.	4.8	11
72	Toll-Like Receptor 9 Stimulation Induces Aberrant Expression of a Proliferation-Inducing Ligand by Tonsillar Germinal Center B Cells in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 1227-1238.	6.1	91

#	Article	IF	Citations
73	Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen Production in IgA Nephropathy. Kidney International Reports, 2017, 2, 1194-1207.	0.8	49
74	Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?. Disease Markers, 2016, 2016, 1-6.	1.3	32
75	Apoptosis inhibitor of macrophage protein enhances intraluminal debris clearance and ameliorates acute kidney injury in mice. Nature Medicine, 2016, 22, 183-193.	30.7	161
76	Beyond the Differences in Tonsillectomy in IgA Nephropathy: From Rationale To Indications in Patients. , 2016, , 311-319.		0
77	Circulating TNF Receptors 1 and 2 Are Associated with the Severity of Renal Interstitial Fibrosis in IgA Nephropathy. PLoS ONE, 2015, 10, e0122212.	2.5	48
78	Pathogenic Role of a Proliferation-Inducing Ligand (APRIL) in Murine IgA Nephropathy. PLoS ONE, 2015, 10, e0137044.	2.5	24
79	FP304ABERRANT APRIL EXPRESSION IN TONSILLAR GERMINAL CENTER B CELLS IN IGA NEPHROPATHY PATIENTS. Nephrology Dialysis Transplantation, 2015, 30, iii168-iii169.	0.7	0
80	Paradigm shift in activity assessment of IgA nephropathy â€“ optimizing the next generation of diagnostic and therapeutic maneuvers via glycan targeting. Expert Opinion on Biological Therapy, 2015, 15, 583-593.	3.1	9
81	TWEAK/Fn14 system and crescent formation in IgA nephropathy. BMC Nephrology, 2015, 16, 27.	1.8	15
82	Altered serum glyceraldehyde-derived advanced glycation end product (AGE) and soluble AGE receptor levels indicate carbonyl stress in patients with schizophrenia. Neuroscience Letters, 2015, 593, 51-55.	2.1	19
83	Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrology Dialysis Transplantation, 2015, 30, 1315-1321.	0.7	99
84	Phenotype of asthma related with high serum periostin levels. Allergology International, 2015, 64, 175-180.	3.3	102
85	Changes in Nephritogenic Serum Galactose-Deficient IgA1 in IgA Nephropathy following Tonsillectomy and Steroid Therapy. PLoS ONE, 2014, 9, e89707.	2.5	72
86	Dietary Zinc Is a Key Environmental Modifier in the Progression of IgA Nephropathy. PLoS ONE, 2014, 9, e90558.	2.5	19
87	Uncoupling of Glomerular IgA Deposition and Disease Progression in Alymphoplasia Mice with IgA Nephropathy. PLoS ONE, 2014, 9, e95365.	2.5	6
88	A Panel of Serum Biomarkers Differentiates IgA Nephropathy from Other Renal Diseases. PLoS ONE, 2014, 9, e98081.	2.5	93
89	Diagnosis and activity assessment of immunoglobulin A nephropathy: current perspectives on noninvasive testing with aberrantly glycosylated immunoglobulin A-related biomarkers. International Journal of Nephrology and Renovascular Disease, 2014, 7, 409.	1.8	17
90	Carbon Ion Beam Radiotherapy for Sinonasal Malignant Tumors Invading Skull Base. Case Reports in Otolaryngology, 2014, 2014, 1-4.	0.2	2

#	Article	IF	Citations
91	Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. Clinical and Experimental Nephrology, 2014, 18, 770-777.	1.6	59
92	Proposal of remission criteria for IgA nephropathy. Clinical and Experimental Nephrology, 2014, 18, 481-486.	1.6	38
93	Development of animal models of human IgA nephropathy. Drug Discovery Today: Disease Models, 2014, 11, 5-11.	1.2	24
94	Serum under-O-glycosylated IgA1 level is not correlated with glomerular IgA deposition based upon heterogeneity in the composition of immune complexes in IgA nephropathy. BMC Nephrology, 2014, 15, 89.	1.8	11
95	Expressions and Roles of Periostin in Otolaryngological Diseases. Allergology International, 2014, 63, 171-180.	3.3	49
96	The Kinetics of Glomerular Deposition of Nephritogenic IgA. PLoS ONE, 2014, 9, e113005.	2.5	13
97	Nationwide survey on current treatments for IgA nephropathy in Japan. Clinical and Experimental Nephrology, 2013, 17, 827-833.	1.6	48
98	Experimental evidence of cell dissemination playing a role in pathogenesis of IgA nephropathy in multiple lymphoid organs. Nephrology Dialysis Transplantation, 2013, 28, 320-326.	0.7	12
99	Amelioration of Angiotensin IIâ€“Induced Salt-Sensitive Hypertension by Liver-Type Fatty Acidâ€“Binding Protein in Proximal Tubules. Hypertension, 2013, 62, 712-718.	2.7	9
100	A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease. Journal of Nephrology, 2013, 26, 350-357.	2.0	88
101	Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients. Nephrology Dialysis Transplantation, 2012, 27, 1090-1097.	0.7	55
102	Development of a Model of Early-Onset IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 1364-1374.	6.1	51
103	Determination of Severity of Murine IgA Nephropathy by Glomerular Complement Activation by Aberrantly Glycosylated IgA and Immune Complexes. American Journal of Pathology, 2012, 181, 1338-1347.	3.8	42
104	Aberrant Glycosylation of IgA1 and Anti-Glycan Antibodies in IgA Nephropathy: Role of Mucosal Immune System. Advances in Oto-Rhino-Laryngology, 2011, 72, 60-63.	1.6	40
105	Different Pathological Roles of Toll-Like Receptor 9 on Mucosal B Cells and Dendritic Cells in Murine IgA Nephropathy. Clinical and Developmental Immunology, 2011, 2011, 1-10.	3.3	26
106	Reevaluation of the Mucosa-Bone Marrow Axis in IgA Nephropathy with Animal Models. Advances in Oto-Rhino-Laryngology, 2011, 72, 64-67.	1.6	12
107	Pathological Role of Tonsillar B Cells in IgA Nephropathy. Clinical and Developmental Immunology, 2011, 2011, 1-8.	3.3	34
108	A Case of Cerebellar Ataxia with EB Virus Infection. Practica Otologica, Supplement, 2011, 130, 124-130.	0.0	1

#	Article	IF	Citations
109	A Case of Piriform Sinus Fistula Occurring Seven Times before Resolution. Practica Otologica, Supplement, 2011, 130, 106-111.	0.0	0
110	Prophylactic Effect and QOL in Cases of Japanese Cedar Pollinosis. Practica Otologica, Supplement, 2011, 130, 44-48.	0.0	0
111	Two Cases of Maxillary Sinus Hematocele Mimicking Malignant Tumors. Practica Otologica, Supplement, 2011, 130, 49-55.	0.0	0
112	Clinical Study of 80 Parotid Gland Tumors. Practica Otologica, Supplement, 2011, 130, 146-151.	0.0	0
113	A Case of Papillary Carcinoma from a Thyroglossal Duct Remnant. Practica Otologica, Supplement, 2011, 130, 184-189.	0.0	0
114	Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. Journal of Clinical Investigation, 2009, 119, 1668-77.	8.2	356
115	Amelioration of Crescentic Glomerulonephritis by RhoA Kinase Inhibitor, Fasudil, through Podocyte Protection and Prevention of Leukocyte Migration. American Journal of Pathology, 2008, 172, 603-614.	3.8	35
116	Potential Immunopathogenic Role of the Mucosaâ€“Bone Marrow Axis in IgA Nephropathy: Insights From Animal Models. Seminars in Nephrology, 2008, 28, 66-77.	1.6	43
117	Toll-Like Receptor 9 Affects Severity of IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2008, 19, 2384-2395.	6.1	160
118	Roles of Bone Marrow, Mucosa and Lymphoid Tissues in Pathogenesis of Murine IgA Nephropathy. , 2007, 157, 164-168.		9
119	The Mucosa-Bone-Marrow Axis in IgA Nephropathy. , 2007, 157, 70-79.		29
120	Th2 cytokine induces aberrant O-glycosylation in the hinge region of IgA1 via downregulation of core1Î²1, 3-galactosyltransferase and its molecular chaperone Cosmc. Juntendoì„ Igaku, 2007, 53, 113-120.	0.1	0
121	Genome-Wide Scan in a Novel IgA Nephropathy Model Identifies a Susceptibility Locus on Murine Chromosome 10, in a Region Syntenic to Human IGAN1 on Chromosome 6q22â€“23. Journal of the American Society of Nephrology: JASN, 2005, 16, 1289-1299.	6.1	67
122	Human bronchial smooth muscle cell proliferation via thromboxane A2 receptor. Prostaglandins Leukotrienes and Essential Fatty Acids, 2004, 71, 375-382.	2.2	11